公开(公告)号：KR1020110045746A

公开(公告)日：2011-05-04

申请号：KR1020090102442

申请日：2009-10-27

Applicant: 한림대학교 산학협력단

Inventor： 강일준 ,  김민주 ,  유상권 ,  임순성 ,  원무호

IPC: A61K36/03 ,  A23L1/30 ,  A61P25/28

Abstract: PURPOSE: A pharmaceutical or functional food composition containing Agarum clathratum extract is provided to enhance acetylcholine concentration and to prevent and treat Alzheimer's disease. CONSTITUTION: A pharmaceutical composition or functional food composition for preventing or treating dementia contains 0.1-99 weight% of Agarum clathratum extract. The Agarum clathratum extract is isolated using water or 50-100% low alcohol of C1-C4. A pharmaceutical composition or functional food composition for improving cognition contains 0.01-15 weight% of the composition .The pharmaceutical composition further contains pharmaceutically acceptable carrier, diluent, or excipient.

Abstract translation: 目的：提供含有Agarum clathratum提取物的药物或功能性食品组合物，以提高乙酰胆碱浓度并预防和治疗阿尔茨海默病。 构成：用于预防或治疗痴呆的药物组合物或功能性食品组合物含有0.1-99重量％的琼脂提取物。 Agarum clathratum提取物用水或50-100％的低级醇C1-C4分离。 用于改善认知的药物组合物或功能食品组合物含有0.01-15重量％的组合物。药物组合物还含有药学上可接受的载体，稀释剂或赋形剂。

公开(公告)号：KR1020090026838A

公开(公告)日：2009-03-16

申请号：KR1020070091867

申请日：2007-09-11

Applicant: 한림대학교 산학협력단 ,  재단법인춘천바이오산업진흥원

Inventor： 최수영 ,  음원식 ,  박진서 ,  김대원 ,  최진희 ,  장상호 ,  고인영 ,  강일준 ,  원무호 ,  권형주 ,  임순성

IPC: A61K31/7048 ,  A61K31/702

CPC classification number: A61K31/704 ,  A61K36/25

Abstract: A 3-O-(beta-D-glucopyranosyl(1->4)-alpha-L-arabinopyranosyl)-hederagenin is provided to be applied to aiding agent, medicine, cosmetic material increasing infiltration efficiency of the cell permeability fusion protein including Tat-SOD etc. and various disease treating field. A 3-O-(beta-D-glucopyranosyl(1->4)-alpha-L-arabinopyranosyl)-hederagenin improves cell permeation rate of cell permeability fusion protein. The cell permeability fusion protein is formed by covalent bonding HIV-Tat(49-57) consisting of 6~15 amino acids, oligolysine, oligoarginine, oligo(lysine and arginine), protein transport domain selected from PEP-1 and cell non-porous protein. The cell permeability fusion protein is HIV-Tat-Cu,Zn superoxide dismutase. The 3-O- (beta-D-glucopyranosyl(1->4)-alpha-L-arabinopyranosyl)-hederagenin is separated from Fatsia japonica.

Abstract translation: 提供3-O-（β-D-吡喃葡萄糖基（1→4）-alpha-L-阿拉伯吡喃糖基）-hederagenin应用于助剂，药物，化妆品，增加细胞渗透性融合蛋白（包括Tat）的渗透效率 -SOD等和各种疾病治疗领域。 3-O-（β-D-吡喃葡萄糖基（1-> 4）-alpha-L-阿拉伯吡喃糖基）-hederagenin提高细胞渗透性融合蛋白的细胞渗透速率。 细胞渗透性融合蛋白是通过共价键合形成的HIV-Tat（49-57）由6〜15个氨基酸，寡聚赖氨酸，寡精氨酸，寡核苷酸（赖氨酸和精氨酸）组成，蛋白质转运结构域选自PEP-1和细胞无孔 蛋白。 细胞渗透性融合蛋白是HIV-Tat-Cu，Zn超氧化物歧化酶。 从Fatsia japonica分离出3-O-（β-D-吡喃葡萄糖基（1-> 4）-alpha-L-阿拉伯吡喃糖基） - 原基因。

公开(公告)号：KR100857691B1

公开(公告)日：2008-09-23

申请号：KR1020070053211

申请日：2007-05-31

Applicant: 한림대학교 산학협력단 ,  재단법인춘천바이오산업진흥원 ,  서림바이오 주식회사

Inventor： 강일준 ,  임순성 ,  박진서 ,  원무호 ,  최수영 ,  권형주 ,  고인영 ,  한승준

IPC: A61K36/533 ,  A61P3/10

CPC classification number: A61K36/53 ,  A23V2200/328 ,  A61K2236/33 ,  A61K2236/35 ,  Y10S514/866

Abstract: A composition comprising an extract of Elsholtzia ciliata is provided to show excellent anti-oxidative activity, advanced glycation end product inhibitory activity and aldose reductase inhibitory action, thereby being used for preventing or treating diabetic complications. A composition for inhibiting diabetic complications comprises an extract of Elsholtzia ciliata, wherein the extract is obtained by using an organic solvent such as C1-5 alcohol, ethylacetate, hexane, acetone, chloroform, and methylene chloride. A food or a medicine for inhibiting the diabetic complications comprises the composition.

Abstract translation: 提供了包含Elsholtzia ciliata提取物的组合物以显示优异的抗氧化活性，晚期糖基化终产物抑制活性和醛糖还原酶抑制作用，从而用于预防或治疗糖尿病并发症。 用于抑制糖尿病并发症的组合物包括Elsholtzia ciliata的提取物，其中通过使用有机溶剂如C 1-5醇，乙酸乙酯，己烷，丙酮，氯仿和二氯甲烷获得提取物。 用于抑制糖尿病并发症的食品或药物包含该组合物。

公开(公告)号：KR1020070063760A

公开(公告)日：2007-06-20

申请号：KR1020050123938

申请日：2005-12-15

Applicant: 한림대학교 산학협력단

Inventor： 임순성 ,  강일준 ,  신현경

IPC: A61K36/9062 ,  A61P3/10

Abstract: A composition for inhibiting diabetes complication comprising a zingiberaceae(Alpinia officinarum) extract is provided to inhibit non-enzymatic glycosylation, binding between lipid peroxide and protein, oxidation and activity of aldose reductase. The composition for inhibiting diabetes complication comprises 0.001-99.9 wt.%, preferably 0.1-50 wt.% of the zingiberaceae(Alpinia officinarum) extract which is prepared by extracting zingiberaceae(Alpinia officinarum) with an organic solvent selected from C1-C5 alcohol, ethylacetate, hexane, acetone, chloroform, methylene chloride, and diluted solution thereof. The daily dosage of the composition is 0.1-100 mg/kg, and the composition is a pharmaceutical or food composition.

Abstract translation: 提供用于抑制糖尿病并发症的组合物，其包含姜科（Alpinia officinarum）提取物以抑制非酶糖基化，脂质过氧化物与蛋白质之间的结合，氧化和醛糖还原酶的活性。 用于抑制糖尿病并发症的组合物包含通过用选自C1-C5醇的有机溶剂萃取姜科（Alpinia officinarum）而制备的姜科（Alpinia officinarum）提取物的0.001-99.9重量％，优选0.1-50重量％ 乙酸乙酯，己烷，丙酮，氯仿，二氯甲烷及其稀释溶液。 组合物的日剂量为0.1-100mg / kg，组合物为药物或食品组合物。